Weight Loss Peptides: What Actually Works and What Does Not

Weight loss peptides are short amino-acid chains that signal appetite, blood sugar, or fat-metabolism pathways. The strongest weight-loss evidence is for GLP-1-based medicines: semaglutide and tirzepatide. Other peptides, including tesamorelin, sermorelin, CJC-1295, ipamorelin, AOD-9604, MOTS-c, and BPC-157, may affect body composition biology but do not have the same human evidence for chronic weight management.

Quick answer: which peptides actually cause weight loss?

The peptides with the clearest human evidence for chronic weight management are semaglutide and tirzepatide, studied over 68 to 72 weeks in large trials 5 6. They work mainly by changing appetite, fullness, and blood-sugar signaling, but they can also cause nausea, vomiting, diarrhea, constipation, gallbladder problems, pancreatitis warnings, kidney injury risk, and other label-listed risks 1 3.

Most other peptides marketed online for “fat loss” are in a different evidence category. Tesamorelin has a real FDA-approved use for excess abdominal fat in adults with HIV-associated lipodystrophy, but that is not the same as general obesity or chronic weight management 7.

What are weight loss peptides?

Weight loss peptides are peptide-based medicines or compounds that affect signals involved in appetite, fullness, insulin release, glucose control, growth hormone, fat storage, or energy use. A peptide is a short chain of amino acids, which are the building blocks of proteins.

The key point is that “peptide” describes structure, not proof. Semaglutide and tirzepatide have large human trials in chronic weight management 5 6. MOTS-c and BPC-157 have mostly early or preclinical research for weight-related questions 12 13.

How peptides differ from other weight-loss drugs

Many peptide medicines mimic body signals. GLP-1 receptor agonists copy a gut-hormone signal that helps regulate appetite, stomach emptying, insulin, and glucagon 1 5. Tirzepatide adds GIP receptor activity to GLP-1 activity, which is why it is called a dual agonist 3 6.

That biology can be powerful, but it is not automatically safe. A clinician still needs to review contraindications, side effects, pregnancy status, diabetes medicines, gallbladder or pancreas history, kidney risk, and whether the medication source is licensed 1 3 10.

Are peptides the same as Ozempic?

No. Ozempic is one brand of semaglutide, a GLP-1 receptor agonist, and it is FDA-approved for adults with type 2 diabetes; Wegovy is the semaglutide brand FDA-approved for chronic weight management 1 2. The broader word “peptides” includes many compounds with very different uses and evidence.

This matters because people often use “peptides” as if it means one category of similar treatments. In reality, semaglutide, tirzepatide, tesamorelin, sermorelin, AOD-9604, MOTS-c, and BPC-157 act on different systems and should not be compared as if they all do the same thing 1 3 7 12 13.

Which peptides have real evidence for weight loss?

The strongest evidence belongs to GLP-1-based medicines, especially semaglutide and tirzepatide, with named trials lasting 68 to 72 weeks 5 6. The benefits are meaningful for many people, but side effects and contraindications are part of the same decision 1 3.

Semaglutide: Wegovy, Ozempic, and compounded semaglutide

Semaglutide is a GLP-1 receptor agonist. Wegovy is FDA-approved for chronic weight management, while Ozempic is FDA-approved for type 2 diabetes and certain cardiovascular-risk uses in adults with type 2 diabetes 1 2. At Chia, we offer compounded semaglutide injection after a licensed-provider evaluation when clinically appropriate.

Mechanistically, semaglutide activates GLP-1 receptors involved in appetite, fullness, insulin release, and glucagon control 1. In STEP 1, adults with overweight or obesity without diabetes received semaglutide 2.4 mg once weekly plus lifestyle intervention; mean body weight decreased 14.9% at 68 weeks, compared with 2.4% with placebo; individual results vary 5.

The trade-off is tolerability and risk. In STEP 1 and the Wegovy label, common adverse events included nausea, diarrhea, vomiting, and constipation; the label also includes warnings about pancreatitis, gallbladder disease, acute kidney injury, increased heart rate, suicidal behavior and ideation, and thyroid C-cell tumor risk 1 5.

Tirzepatide: Zepbound, Mounjaro, and compounded tirzepatide

Tirzepatide is a GIP/GLP-1 dual agonist. Zepbound is FDA-approved for chronic weight management, while Mounjaro is FDA-approved to improve blood sugar control in adults with type 2 diabetes 3 4. At Chia, we offer compounded tirzepatide tablets and injection when a licensed provider determines it is clinically appropriate.

Tirzepatide acts on both GIP and GLP-1 receptors, two incretin pathways involved in appetite and glucose regulation 3 6. In SURMOUNT-1, adults with obesity or overweight without diabetes received tirzepatide 5 mg, 10 mg, or 15 mg once weekly; mean body-weight reductions at 72 weeks were 15.0%, 19.5%, and 20.9%, compared with 3.1% with placebo; individual results vary 6.

The main adverse events in SURMOUNT-1 were gastrointestinal and often occurred during dose escalation 6. The Zepbound label includes warnings about pancreatitis, gallbladder disease, acute kidney injury, severe gastrointestinal disease, hypoglycemia risk when used with insulin or insulin secretagogues, suicidal behavior and ideation, and thyroid C-cell tumor risk 3.

Retatrutide: investigational triple agonist

Retatrutide is an investigational GIP/GLP-1/glucagon receptor agonist. It is not FDA-approved for any use, is not available for prescribing, and cannot be legally compounded; this section is education only 9.

Retatrutide is designed to activate three metabolic hormone receptors instead of one or two. In a phase 2 trial, once-weekly retatrutide was associated with dose-related weight reduction at 48 weeks, but adverse events included gastrointestinal symptoms and heart-rate increases, and long-term safety is still being studied 9.

Which peptides support body composition but do not drive weight loss?

Some peptides may affect visceral fat, lean mass, growth-hormone signaling, tissue repair, or metabolic stress, but that is not the same as proven weight loss. For these peptides, the honest answer is usually narrower: interesting mechanism, some human data for select uses, but not the same chronic-weight-management evidence seen in large GLP-1 trials 5 6.

Tesamorelin: visceral fat and HIV-associated lipodystrophy

Tesamorelin is a growth hormone-releasing hormone analog, also called a GHRH analog. It prompts the pituitary gland to release growth hormone, which can raise IGF-1 and affect visceral adipose tissue, the deeper abdominal fat around organs 7 8.

Its evidence is real but specific. Tesamorelin is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and trials in that population showed reduced visceral adipose tissue 7 8. It should not be treated as a general belly-fat or obesity medication.

Safety is also specific. The tesamorelin label notes risks and precautions around malignancy, increased IGF-1, glucose intolerance or diabetes, fluid retention, injection-site reactions, hypersensitivity, and pregnancy 7.

Sermorelin, CJC-1295, and ipamorelin

Sermorelin is a GHRH analog, while CJC-1295 is a longer-acting GHRH analog and ipamorelin is a growth hormone secretagogue that works through ghrelin-related signaling. Their shared theme is the GH-axis, not direct appetite suppression like GLP-1 medicines.

For weight loss, the evidence is limited. Older sermorelin research showed that GHRH analogs can stimulate growth-hormone release, but that is not the same as showing large, durable fat loss in adults with obesity 15. CJC-1295 and ipamorelin are commonly discussed for body composition, sleep, and recovery, but they do not have STEP- or SURMOUNT-level obesity outcomes 5 6.

At Chia, sermorelin is part of our longevity catalog in injection, nasal spray, and tablet forms, and it may be used in clinician-guided protocols such as GLP-1 + Sermorelin. Possible safety issues for GH-axis peptides include fluid retention, joint discomfort, numbness or tingling, glucose effects, and the need to avoid unsupervised “research chemical” sources.

AOD-9604

AOD-9604 is a modified fragment of human growth hormone. The idea is that a smaller GH-derived fragment might influence fat metabolism without the full growth-promoting effects of growth hormone, but that idea has not translated into a standard obesity medicine 14.

Human evidence remains much weaker than for semaglutide or tirzepatide. Early studies investigated AOD-9604 in people with obesity, but it is not an FDA-approved chronic weight-management medication and is not offered by Chia 14.

The practical concern is quality and monitoring. If a peptide is sold online without a prescription as “research use only,” the patient may have no reliable review of sterility, potency, drug interactions, or whether the compound fits their medical history 10.

MOTS-c

MOTS-c is a mitochondrial-derived peptide. In plain language, it is linked to cell energy signaling, and early research suggests it may influence metabolic stress pathways 12.

For weight loss, the evidence is early. Much of the MOTS-c literature is preclinical, including animal and cell research, so it cannot be compared with large human obesity trials of semaglutide or tirzepatide 5 6 12.

Safety expectations should stay modest. Without large human trials for chronic weight management, clinicians cannot confidently define expected weight change, long-term adverse events, or ideal monitoring for MOTS-c in weight-loss use 12.

BPC-157

BPC-157 is a peptide studied mainly in tissue-repair, tendon, wound, and gastrointestinal models. Its proposed mechanisms involve local healing signals, angiogenesis pathways, and inflammation-related biology, not primary appetite control 13.

For weight loss, BPC-157 is not in the same evidence category as GLP-1 medicines. The available literature does not establish it as a human chronic-weight-management treatment, and Chia does not list BPC-157 as an offering 5 6 13.

The safety concern is the gap between online claims and human data. Combination use, long-term exposure, product purity, and patient-specific risks have not been well defined for weight-loss use 10 13.

How much weight can you expect to lose on peptides?

Expected weight change depends on the compound, baseline weight, nutrition, activity, medical history, side effects, and treatment duration. In large trials, semaglutide and tirzepatide produced average weight reductions over 68 to 72 weeks, but individual results vary 5 6.

In STEP 1, semaglutide 2.4 mg once weekly plus lifestyle intervention was associated with 14.9% mean body-weight reduction at 68 weeks 5. In SURMOUNT-1, tirzepatide once weekly was associated with 15.0% to 20.9% mean body-weight reduction at 72 weeks, depending on the studied dose 6.

Those active-ingredient trial numbers should be balanced with safety. Both Wegovy and Zepbound labels describe common gastrointestinal side effects and serious warnings, including pancreatitis, gallbladder disease, kidney injury, suicidal behavior and ideation, and thyroid C-cell tumor risk in people with a personal or family history of medullary thyroid carcinoma or MEN2 1 3.

Do peptides get rid of belly fat?

No peptide can choose where your body loses fat first. GLP-1 medications can reduce total body weight, which may include abdominal fat, but they do not spot-reduce belly fat over one chosen area 5 6.

Tesamorelin is the special case people ask about. It is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and trials measured reductions in visceral adipose tissue in that specific group 7 8.

That does not make tesamorelin a general belly-fat treatment. Its label includes safety concerns around IGF-1, glucose, malignancy considerations, fluid retention, hypersensitivity, and pregnancy, so benefit and risk must be judged in the right patient population 7.

What are the side effects and safety considerations?

Side effects depend on the exact peptide. For semaglutide and tirzepatide, gastrointestinal symptoms are common, and both labels include serious warnings that should be reviewed before treatment starts and during follow-up 1 3.

• Common GLP-1 and GIP/GLP-1 side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, reflux, burping, and reduced appetite 1 3.
• Serious label warnings include pancreatitis, gallbladder disease, acute kidney injury from dehydration, severe allergic reactions, increased heart rate, and suicidal behavior and ideation 1 3.
• Wegovy and Zepbound labels include a boxed warning and contraindication for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 1 3.
• Labels advise stopping Wegovy or Zepbound when pregnancy is recognized because weight loss offers no benefit during pregnancy and may harm the fetus 1 3.
• Tesamorelin labeling includes precautions for malignancy, glucose intolerance, increased IGF-1, fluid retention, hypersensitivity, and injection-site reactions 7.
• For research peptides, the major safety questions are human evidence, sterility, potency, identity, and whether the product is being used without a licensed clinician or licensed pharmacy oversight 10.

This is why source matters. A licensed provider can screen for contraindications and monitor side effects, while a state-licensed 503A pharmacy can compound for an individual patient with a valid prescription; no-prescription “research chemical” vendors do not provide that same clinical path 10.

Who is a candidate for weight loss peptides?

A candidate is someone whose medical history, BMI, goals, and risks fit a clinician-supervised plan. Eligibility is individualized, and it must account for conditions like type 2 diabetes, kidney disease, gallbladder disease, pregnancy, and medication interactions 1 3.

Wegovy and Zepbound labels include chronic weight-management indications for adults with obesity or adults with overweight and at least one weight-related condition, along with reduced-calorie diet and increased physical activity 1 3. Ozempic and Mounjaro have type 2 diabetes labels, so they should not be treated as interchangeable weight-loss approvals 2 4.

People may not be candidates if they are pregnant, have a personal or family history of medullary thyroid carcinoma or MEN2, have had a serious allergy to the medication, or have medical issues that increase risk from dehydration, severe gastrointestinal symptoms, pancreatitis, gallbladder disease, or hypoglycemia 1 3.

How can you get weight loss peptides through a licensed provider?

The safer path is a licensed clinical evaluation, clear medication review, provider-guided follow-up, and dispensing from a licensed pharmacy source. At Chia, treatment is 100% online: a short health questionnaire, licensed US provider review, and prescribing only when clinically appropriate.

For GLP-1-based weight-loss care, Chia offers semaglutide injection, with plans currently starting at $249/mo, and tirzepatide tablets or injection, with tablet plans currently starting at $249/mo and injection plans currently starting at $299/mo. Microdosing plans are available for both semaglutide and tirzepatide when a provider determines that approach fits the patient.

Chia also offers select longevity-focused options, including sermorelin, NAD+, and glutathione, and protocols such as Weight + Energy, which includes NAD+ injection plus a choice of GLP-1. These options are clinician-guided; they are not a claim that non-GLP-1 peptides cause weight loss.

If prescribed, medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Dosing is provider-guided and adjusted over time, and patients can message the care team through the patient portal between visits.

We encourage patients to avoid no-prescription peptide sellers and “research use only” products for self-use. The safer comparison is not brand versus compounded; it is licensed clinical care and licensed pharmacy dispensing versus unlicensed self-experimentation 10.

Frequently asked questions

Keep reading

Weight Loss

Peptide Injections for Weight Loss: What Actually Works

Peptides

USA Peptides: What “Research-Only” Means and Legal Ways to Access Peptides

Peptides

Peptide Cheat Sheet: Patient Reference to Common Peptides, Uses, and Dosing